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Vif is dispensable for simian immunodeficiency virus (SIV) replication in some cells, termed permissive (i.e., CEM-SS), but not in others,
termed non-permissive (i.e., H9, CEMx174, and peripheral blood lymphocytes). Non-permissive cells express the RNA editing enzyme,
APOBEC3G. To determine whether vif mRNA could be alternatively spliced, a mutation altering the putative vif splice acceptor site (SA1)
was introduced into SIVmac239 (SIVDvif-SA). Despite three consensus splice acceptor sites nearby SA1, SIVDvif-SA did not efficiently generate
alternatively spliced vif mRNA. SIVDvif-SA was growth attenuated in CEMx174 and H9 cells but not in CEM-SS cells. Following SIVDvif-SA,
but not SIVmac239, infection in either H9 or CEMx174 cells viral cDNA contained numerous G to A mutations; no such differences were
observed in CEM-SS cells. This pattern is consistent with mutations generated by APOBEC3G in the absence of Vif. Therefore, efficient
splicing of SIV vif mRNA is tightly controlled and requires the SA1 site.
D 2005 Elsevier Inc. All rights reserved.Keywords: mRNA; DNA hypermutation; APOBEC3G; Real-time polymerase chain reaction; Cytosine deamination; AIDSIntroduction
Lentiviruses, excluding equine infectious anemia virus,
contain the accessory gene vif. Replication of human
immunodeficiency virus (HIV) in the absence of func-
tional Vif is unaffected in some cell types, termed
permissive (such as SupT1 and CEM-SS), while required
in others, termed non-permissive (such as peripheral blood
mononuclear cells, macrophages, and H9 cells). Recent
data indicate that Vif counters the antiviral effects of the
cytosine deaminase APOBEC3G (Mangeat et al., 2003;
Mariani et al., 2003; Sheehy et al., 2002), and possibly the
closely related APOBEC3F (Wiegand et al., 2004; Zheng
et al., 2004). APOBEC3G deaminates cytosine residues on0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.007
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E-mail address: ewrobins@uci.edu (W.E. Robinson).the nascent viral genome during reverse transcription,
resulting in non-functional proviruses containing G to A
mutations (Mangeat et al., 2003; Suspene et al., 2004).
Additionally, viral replication may be inhibited directly
through degradation of mutated cDNAs via the action of
uracil DNA glycosylase (Harris et al., 2003; Mariani et al.,
2003). Recent data also indicate that APOBEC3G may
have additional antiviral effects separate from cytosine
deamination. Several investigators have shown that APO-
BEC3G containing active site mutations retains antiviral
activity when overexpressed (Newman et al., 2005; Shindo
et al., 2003; Turelli et al., 2004). Vif counters APO-
BEC3G antiviral activity by targeting it for degradation
(Conticello et al., 2003; Marin et al., 2003; Mehle et al.,
2004; Sheehy et al., 2003; Stopak et al., 2003) as part of
the Vif-Cul5-Scf complex (Yu et al., 2003), thereby
preventing APOBEC3G incorporation into the virion (Yu
et al., 2003).05) 281 – 291
Fig. 1. Genomic organization and splicing of SIV RNA. (A) SIV encodes
gag, pol, and envelope proteins plus additional regulatory proteins, Tat and
Rev, and accessory proteins Vif, Vpr, Vpx, and Nef. The 5Vand 3VLTRs are
critical for viral replication. Splicing of rev, nef, tat, and vif mRNAs occurs
through splice donor site 1 (SD1) or an alternate splice donor site (SD1V) in
the 5VLTR to several downstream splice acceptor sites (SA1 to SA4).
Superscript letters denote alternative splice acceptor sites. Rev, Nef, and Tat
can be translated at least three different, multiply spliced mRNAs. Inclusion
of a small, non-coding exon (EX1) (light grey box) is present in some
alternatively spliced forms of rev, tat, nef, and env. (B) Strong consensus
sequences within 250 base pairs of the putative vif splice acceptor sequence,
SA1, are aligned and denoted as SA1a, SA1b, and SA1c. Underlined
sequences match the SIV consensus splice acceptor sequence (Reinhart et al.,
1996; Viglianti et al., 1990) illustrated at the bottom. Asterisks indicate
engineered mutations to generate SA1-deficient virus (SIVDvif-SA).
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viruses such as murine leukemia virus and simian
immunodeficiency virus (SIV) (Harris et al., 2003;
Mangeat et al., 2003). Overexpression of APOBEC3G
orthologues results in species-specific differences during
HIV or SIV infection (Mangeat et al., 2003; Mariani et al.,
2003; Yu et al., 2003). For example, both mouse and
African green monkey (AGM) APOBEC3G disrupt HIV
viral replication regardless of Vif expression (Mariani et
al., 2003). Sensitivity to HIV Vif can be restored by a
single amino acid substitution of aspartic acid for lysine at
residue 128 of AGM APOBEC3G (Bogerd et al., 2004;
Mangeat et al., 2004; Schrofelbauer et al., 2004). Vif from
SIVagm is active against monkey APOBEC3G but not
human APOBEC3G (Mariani et al., 2003; Takeuchi et al.,
2005; Yu et al., 2004a). SIVmac239 Vif is more broadly
reactive and is capable of targeting human, rhesus, and
AGM APOBEC3G for degradation (Gaddis et al., 2004;
Mariani et al., 2003).
While a great deal of study has focused on the
mechanism of APOBEC3G/Vif interactions and antiviral
effects, regulation of Vif transcription and expression
remains understudied. Productive SIV infection requires
both a temporal regulation and balance between at least 20
different splicing events to generate mRNAs encoding
accessory proteins, viral polyproteins, and genomic RNA
(Amendt et al., 1994; Reinhart et al., 1996; Viglianti et al.,
1990). Multiple-spliced 2.0-kb class mRNA messages
encoding Rev, Tat, and Nef are first transcribed and
expressed. Rev and Tat facilitate transcription and nuclear
export of single-spliced 4.0-kb class mRNA encoding
accessory proteins and envelope glycoproteins and the
9.2-kb mRNA encoding Gag and Pol polyproteins or
unspliced genomic RNA (Furtado et al., 1991; Reinhart et
al., 1996; Schwartz et al., 1991; Unger et al., 1991; Viglianti
et al., 1990). Adding to this complexity, significant
variability in the SIV consensus splice acceptor sequence,
(U/C)N(C/U)AG/(G/A) (Amendt et al., 1994; Park et al.,
1991; Reinhart et al., 1996; Unger et al., 1991; Viglianti et
al., 1990), allows for potential alternative splicing of viral
mRNA (Fig. 1).
Direct sequencing of mRNA reveals more than three
alternative splice sites for rev, tat, and nef within 100 base
pairs of the authentic splice sites in both infectious
molecular clones (Park et al., 1991; Unger et al., 1991)
and uncloned isolates from sooty mangabey monkeys
(SIVsmm) (Reinhart et al., 1996) (Fig. 1). In addition to
multiple downstream splice acceptor sites, alternative
splicing of rev, tat, and nef can occur from one of two
splice donor sites within the viral LTR, SD1, and SD1V.
Mechanisms of alternative splice site choice for SIV have
not been characterized; however, HIV alternative splicing is
tightly regulated by cis-acting purine-rich exonic splicing
enhancers (ESEs) (Caputi and Zahler, 2002; Reinhart et al.,
1996) and pyrimidine-rich exonic splicing silencers (ESSs)
(Bilodeau et al., 2001; Domsic et al., 2003).Published reports suggest vif mRNA is the product of a
single splicing event (Garrett et al., 1991; Park et al., 1991;
Schwartz et al., 1991; Viglianti et al., 1990). The putative
SIV vif splice acceptor site (SA1), identified by northern
hybridization, genomic position, and sequence, is located in
the carboxyl terminus of integrase (IN) (Fig. 1). No
alternatively spliced forms of vif have been reported;
however, levels of spliced vif mRNAs are low throughout
the course of infection, thus infrequent use of alternative
splice sites may not be easily detected (Schwartz et al.,
1991; Viglianti et al., 1990).
While much study has focused on the role of HIV Vif and
its interaction with APOBEC3G these interactions are
understudied in SIV replication, arguably the best animal
model for HIV. In this study, we mutated the putative vif-
splice acceptor site, SA1, in SIVmac239 and measured viral
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SIV from both Vif permissive and non-permissive cell lines.
These results demonstrate that vif splicing must occur at SA1
for Vif to be expressed at adequate levels to counteract the
antilentiviral properties present in vif non-permissive cells,
indicating that splicing of vif mRNA is tightly controlled.Fig. 2. Replication of SIVDvif-SA in vif non-permissive and permissive cells.
Equal amounts, as measured by RTassay, of SIVmac239 (circles) or SIVDvif-SA
(triangles) were inoculated upon either (A) semi-permissive CEMx174, (B)
non-permissive H9 cells, or (C) permissive CEM-SS cells at a multiplicity of
infection of less than one. Closed and open symbols represent duplicate
infections. Infections were monitored by IFA using a modification of the
methods for HIV, described previously (King and Robinson, 1998; Robinson
et al., 1989).Results
Mutation of the SIV SA1 splice acceptor site leads to a
growth defect in Vif non-permissive cells
Although no reports have conclusively demonstrated that
messages spliced at SIV SA1 encode for functional Vif
protein, both its genomic position and Northern blot analysis
have led to the conclusion that it is the authentic vif splice
acceptor site (Park et al., 1991; Viglianti et al., 1990).
However, three strong consensus sequences are also located
within 200 base pairs of SA1 (Fig. 1B). Using site-directed
mutagenesis, mutations in the consensus SIV SA1 sequence,
UACAGA to UAUCGC (nucleotides 5463–5468), were
introduced to generate SIVDvif-SA (Fig. 1B). The mutations
were silent within the overlapping IN coding sequence.
SIVDvif-SA failed to replicate in H9 cells (Fig. 2A), known to
express APOBEC3G which confers a Vif non-permissive
phenotype for both HIVDvif and SIVDvif (Mangeat et al.,
2003; Sheehy et al., 2003; Zhang et al., 2003). Replication of
SIVDvif-SA in CEMx174 cells was severely attenuated (Fig.
2B). Vif-deficient SIV have been reported to be either
attenuated (Park et al., 1994; Zou and Luciw, 1996) or
replication incompetent (Desrosiers et al., 1998) in
CEMx174 cells. Levels of APOBEC3G in CEMx174 cells
are comparable to those in H9 cells (data not shown and
Takeuchi et al., 2005). SIVDvif-SA replication in cells lacking
APOBEC3G, CEM-SS, is superimposable on that of the
reference strain (Fig. 2C). Taken together, these data indicate
that despite multiple strong consensus sequences nearby
SA1, SIVDvif-SA replicates with Vif-deficient kinetics.
Splicing of SIV vif mRNA
To ascertain whether alternative splice acceptor sites for
vif could be used in the absence of the consensus SA1 site,
SIV cDNA was generated by reverse transcriptase polymer-
ase chain reaction (RT-PCR) from cellular RNA. Total
cellular RNA was extracted from CEMx174 cells 4 days
after inoculation with either SIVDvif-SA or SIVmac239. Viral
cDNA was generated using a primer which binds down-
stream of the vif start codon. Spliced RNAs were enriched
by amplifying across the splice junction (Fig. 3A). Southern
hybridization of the cDNA revealed a product of the
predicted size for SD1 to SA1 splicing during SIVmac239
infection that was absent in CEMx174 cells infected with
SIVDvif-SA (Fig. 3B). Additionally, significant hybridization
was observed to a larger, potentially alternatively spliced
Fig. 3. Splicing of vif mRNA. (A) Primer S-Vif-REV was used to generate cDNA from CEMx174 cells infected with either SIVmac239 or SIVDvif-SA. cDNAwas
enriched for either authentic spliced message or alternatively spliced products by PCR using the S-M667/S-IN-Rev or S-M667/S-SA1V-Rev primer sets,
respectively. Radiolabeled S-AA55 was used to probe PCR products spliced at either the SD1 or SD1V5Vsplice sites. (B) RT-PCR products from S-M667/S-IN-
REV amplification were transferred to zeta probe (BioRad) membrane and probed with 32P-labeled S-AA55. The asterisk indicates the expected size of
products spliced from SD1 to SA1, while the open arrow indicates a potential, alternatively spliced product. (C) RT-PCR products, performed in duplicate, from
RNA extracted at either 24, 48, or 72 h post-inoculation were amplified using the S-M667/S-SA1V-Rev primer set and probed with labeled S-AA55.
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This product was not present when blots were analyzed
using a probe that bound between SD1 and SD1V(data not
shown) indicating a preferential usage of SD1V in the
putative alternatively spliced product. To distinguish alter-
native versus cryptic splicing, cDNA products were
enriched for splicing events that occurred upstream of
SA1 using the S-SA1V-Rev primer (Fig. 3A, dotted line).
These reactions, performed in duplicate, indicate an
unmasking of a cryptic splice site when SA1 is mutated,
rather than alternative splicing, as no product is observed in
the SIVmac239 samples (Fig. 3C).Fig. 4. Inefficient splicing from SD1Vto a cryptic splice acceptor site. Products fro
sequenced with both T7 and T3 primers using automated sequencing. (A) Expect
SD1-SA1 junction was present in 4/4 clones tested. A single clone of SIVDvif-S
consensus splice acceptor sequence (5V-AGAAG-3V) 308 bp upstream of SA1. In t
retaining the engineered SA1 splice site mutations. The nucleotide sequence of eSequence of SIVDvif-SA-spliced products
To determine if this cryptic splicing occurred at one of
the three nearby consensus sequences (Fig. 1B), cDNA
products of SIVmac239 and SIVDvif-SA were cloned into the
pCR-Script cloning vector and sequenced. Sequences from
SIVmac239-infected cells demonstrated correct splicing from
the 5Vsplice donor site, SD1, within the viral 5V-LTR to the
SA1 sequence (Fig. 4B). All of the cDNA sequences
analyzed from SIVDvif-SA confirmed the presence of the
engineered mutations; surprisingly, none of the clones were
spliced at any of the three consensus splice acceptorm RT-PCR were cloned into pCR-SCRIPT (Stratagene) cloning vectors and
ed splicing pattern for vif mRNA. (B) cDNA from SIVmac239 spliced at the
A was identified that spliced from the alternative 5VSD1Vsite and a near
he remaining four clones SIVDvif-SA cDNA reads through the IN sequence,
ach group of clones is illustrated.
Fig. 5. Kinetics of reverse transcription for SIVDvif-SA in semi-permissive
CEMx174 cells. Quantitative real-time PCR was performed on CEMx174
cellular lysates between 1 and 72 h post-inoculation with either SIVmac239
(closed circles) or SIVDvif-SA (open triangles). At each time point 1.0  106
cells were lysed. Lysates from the equivalent of 2.0  105 cells were
amplified with primers design to detect either (A) -sssDNA (S-AA55/
S-M667) or (B) complete products of reverse transcription (S-M661/
S-M667). Infected cell equivalents were calculated from standard curves
generated by serial dilution of SIVmac251 chronically infected H9 cell lysates
into lysates from uninfected H9 cells. PCR reactions are representative of
duplicate experiments.
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recovered, contained a spliced product approximately 750
bp in length that utilized a loose consensus splice acceptor
sequence, GAAG/TAA located at position 5160, over 300
base pairs upstream of SA1. Consistent with the hybridi-
zation of spliced cDNA (Fig. 3A and data not shown), the
SIVDvif-SA message utilized the alternative 5V splice donor
site, SD1V. Several clones from both SIVmac239 and SIVDvif-SA
contained non-viral sequences which had a high degree of
homology with human chromosome 11 (data not shown),
whichmay account for some of the non-specific bands seen in
Fig. 3B.
Decreased cDNA synthesis is observed during initial
infection of CEMx174 cells with SIVDvif-SA
Considering SIVDvif-SA growth kinetics (Fig. 2) mirrored
that of Vif-deleted virus (Desrosiers et al., 1998; Gibbs et
al., 1994; Park et al., 1994; Zou and Luciw, 1996), it is
unlikely that the cryptically spliced vif mRNA is capable of
encoding sufficient levels of Vif to counteract the antiviral
effects of APOBEC3G. We therefore employed a more
sensitive technique, quantitative real-time PCR, to measure
growth kinetics during the first round of infection.
Previously, we demonstrated that SYBR green-I quantita-
tive real-time PCR using HIV-specific primers is a sensitive
and reproducible method to distinguish defects associated
with impaired HIV entry, reverse transcription, and proteo-
lytic processing (Victoria et al., 2003). Using SIV-specific
primer pairs, homologous to the previously characterized
HIV primers, the replication of SIVDvif-SA in CEMx174
cells was studied. A minimal effect on viral entry was
observed, as seen by similar levels of SIV minus strand
strong stop DNA (-sssDNA) between 1 and 24 h post-
inoculation (Fig. 5A). However, a greater than 90%
reduction in completely reverse transcribed cDNA was
observed throughout infection (Fig. 5B). These results
mirror SIV infection in the presence of the RT inhibitor
PMPA (data not shown). Since neither a non-coding
nucleotide change in IN nor mutation of SA1 would be
expected to cause a reverse transcription defect, these data
are consistent with the degradation of provirus mutated by
APOBEC3G reported for infections with HIV lacking Vif
in non-permissive cells (Goncalves et al., 1996; Mariani et
al., 2003; Sova and Volsky, 1993; von Schwedler et al.,
1993). Integration itself was not adversely affected, as no
defect was observed using the recombinant IN from
SIVDvif-SA in in vitro assays or in vivo by measuring the
accumulation of two-LTR circle DNA, a by-product of
failed integration (data not shown).
Mutational frequency of SIVDvif-SA
DNAwas extracted 48 h post-inoculation from CEM-SS,
CEMx174, or H9 cells infected with either SIVmac239 or
SIVDvif-SA. The IN genes from each virus were amplified andcloned. Multiple clones from triplicate infections were
subjected to sequence analysis. Overall mutational frequency
in IN genes was statistically higher during SIVDvif-SA
infection than in SIVmac239 in both H9 and CEMx174 cells.
This increased frequency was driven by G to A mutation,
indicative of APOBEC3G-mediated cytosine deamination.
Indeed, during SIVDvif-SA infections 1.5% of all guanine
residues sequenced were mutated to adenine in H9 (19 of
1233) and CEMx174 (26 of 1781). Conversely, infections
with SIVmac239 displayed only 0.12% mutational frequency
of guanines in CEMx174 cells (2 of 1707) and no such
mutations in H9 cells. The G to A mutational frequency of
SIVDvif-SA in permissive CEM-SS cells was not statistically
different from SIVmac239 (Fig. 6A). Although the increase in
G to A mutations in Vif non-permissive cells is substantial,
Fig. 6. G toA andA toGmutational frequencies of SIVmac239 and SIVDvif-SA.
Whole cell lysates were obtained from H9, CEMx174, or CEM-SS cells
infected with either SIVmac239 or SIVDvif-SA 120 h post-inoculation.
Following PCR amplification of the IN gene, automated sequencing was
performed. In H9 cells, six SIVmac239 clones (3386 bp) and ten SIVDvif-SA
clones (7835 bp) were sequenced. In CEMx174 cells, fourteen clones of both
SIVmac239 (9858 bp) and SIVDvif-SA (9717 bp) were sequenced. In CEM-SS
cells, five SIVmac239 clones (4034 bp) and four SIVDvif-SA clones (3096 bp)
were sequenced. Panel A: G to A mutational frequency; or panel B: A to G
mutational frequency for each cell type inoculated with either SIVmac239
(open bars) or SIVDvif-SA (shaded bars). Asterisks indicate statistical
significance ( P < 0.05) by one-tailed two-sample t test assuming unequal
variance.
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for vif-deleted HIV in non-permissive cells (1.1–14%)
(Mangeat et al., 2003; Suspene et al., 2004; Yu et al.,
2004b, 2003; Zhang et al., 2003). The relatively low
frequencies observed here could be due to inherent differ-
ences between HIV and SIV susceptibility to human
APOBEC3G. However, we cannot rule out low level
expression of Vif from cryptically spliced vif mRNA during
SIVDvif-SA infection.
By far the second most common mutation observed
was an A to G. Strikingly, A to G mutations (Fig. 6B)
exceed G to A (Fig. 6A) mutations in both H9 and
CEMx174 cells when Vif was present. These data,
combined with the relatively similar A to G mutationalfrequencies in H9 and CEMx174 cells in the presence of
Vif, suggest that A to G mutations were not Vif regulated.
However, in H9 cells A to G mutations were increased in
the absence of Vif. A to G mutations have been observed
previously (Kobayashi et al., 2004; Mangeat et al., 2003;
Wiegand et al., 2004) as the second most common
mutation during HIV Vif-deficient viral replication in
non-permissive cells and may be the result of another
cellular editing enzyme.Discussion
While many studies have focused on APOBEC3G
interactions with Vif (Conticello et al., 2003; Marin et al.,
2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al.,
2003; Yu et al., 2003), expression of APOBEC3G (Rose et
al., 2004; Sheehy et al., 2002), and species-specific antiviral
activities of APOBEC3G (Bogerd et al., 2004; Kobayashi et
al., 2004; Lake et al., 2003; Mangeat et al., 2004; Mariani et
al., 2003; Schrofelbauer et al., 2004; Xu et al., 2004), this is
the first study to report a tightly controlled transcription of
vif mRNA through splicing at SA1. Despite significant
selective pressure on SIVDvif-SA, efficient splicing of vif
mRNA at one of three strong consensus splice acceptor
sequences nearby SA1 was not observed. In fact, only a low
level of splicing, through a cryptic splice site that
preferentially utilized the unconventional upstream SD1V
site, was observed. This finding is in sharp contrast to
mutational analyses of HIV splice acceptor sites 2–4, in
which many cryptic and alternative splice sites were
identified (Purcell and Martin, 1993).
In addition to consensus splice donor and splice acceptor
sequences, splicing is governed by several cis-acting
elements: intron branch point sequences, ESSs, ESEs, and
intronic polypyrimidine tracts (reviewed in Garcia-Blanco,
2003; Nilsen, 2003). Because degenerate branch point
sequences are located throughout the SIV genome, it is
unlikely that alternative splicing at SA1a, SA1b, or SA1c is
prohibited via this mechanism. ESEs control the alternative
splicing of rev, tat, and nef through recruitment of ASF/
SF2, Srp40, SC35, and other serine/arginine-rich (SR)
proteins in HIV (Bilodeau et al., 2001; Caputi and Zahler,
2002; Domsic et al., 2003; Reinhart et al., 1996; Ropers et
al., 2004). At least five ESSs have been identified for HIV
(ESSI-ESSV) as well as purine-rich ESEs for both HIV and
SIVsmm (Caputi and Zahler, 2002; Reinhart et al., 1996). No
putative strong SR protein binding sites were identified near
SA1a, SA1b, or SA1c using the ESEfinder Web interface
(Cartegni et al., 2002). However, ESEfinder also failed to
identify any significant ESE binding sites for SIV nearby
SA1, despite evidence of a weak ESE that binds ASF/SF2 to
enhance splicing at SA1 for HIV (Ropers et al., 2004).
Although several ESS sequences have been identified for
HIV (Bilodeau et al., 2001; Caputi and Zahler, 2002;
Domsic et al., 2003), no studies have been performed to
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and rev during infection may be in part due to extensive
12–20 nucleotide polypyrimidine tracts immediately
upstream of the SA2, SA3, and SA4 3V splice sites. No
such polypyrimidine tracts are located upstream of either the
SA1a, SA1b, or SA1c sites; however, the upstream sequence
of SA1 contains only a single short, 10-base pair interrupted
polypyrimidine tract. Data presented here suggest lack of a
strong polypyrimidine tract and a potential unidentified ESS
may be acting to repress splicing of vif mRNA at alternative
splice sites nearby SA1.
Due to this tightly controlled expression of vif mRNA,
replication of SIVDvif-SA is consistent with the phenotype of
viruses containing deleted or otherwise non-functional vif.
In CEMx174 cells, SIV lacking vif has been reported to be
completely replication incompetent (Desrosiers et al., 1998),
severely attenuated (Park et al., 1994), or mildly attenuated
(Zou and Luciw, 1996). SIV containing point mutations in
the start codon or premature stop codons of vif display a
growth delay of 35 days and reach only 33% of the maximal
RT activity of SIVmac239 in CEMx174 cells (Park et al.,
1994). Similarly, we demonstrate that CEMx174 cells, at
least those that we have used, are best characterized as semi-
permissive. Growth of SIVDvif-SA in CEMx174 is delayed
by greater than 14 days and only a maximum of 40% of the
cells were positive for SIV antigens by indirect immuno-
fluorescence assay (IFA) (Fig. 2A). We observed no viral
replication in the truly non-permissive cell line, H9 (Fig.
2B). Conversely, SIVDvif-SA replication in permissive CEM-
SS cells mirrored that of SIVmac239 (Fig. 2C). This latter
finding is important because it suggests that only vif is being
affected by the mutation. SIVmac239 and SIVsmm produce a
measurable fraction of mRNAs that utilize SA1 to generate
a small non-coding exon, EX1, in alternatively spliced tat,
rev, and nef (Fig. 1) (Reinhart et al., 1996; Unger et al.,
1991; Viglianti et al., 1990). Our data suggest that inclusion
of EX1 is not necessary for SIV replication as SIVDvif-SA
replication in CEM-SS cells was unaffected. Previous
studies on exons 2 and 3 of HIV demonstrated that inclusion
of exon 3 can reduce protein expression (Krummheuer et al.,
2001). For SIV, inclusion of exon 1 would appear to have
little positive or negative effect.
Defects associated with vif deletion in HIV include
abnormal viral core assembly (Borman et al., 1995;
Gabuzda et al., 1992; Mariani et al., 2003; Sakai et al.,
1993; von Schwedler et al., 1993), decreased proviral
cDNA synthesis (Borman et al., 1995; Gabuzda et al.,
1992; Mariani et al., 2003; Sakai et al., 1993; von
Schwedler et al., 1993), misincorporation of envelope with
abnormal posttranslational modification of gp41 (Gaddis et
al., 2003), G to A hypermutability in the viral genome
(Harris et al., 2003; Kobayashi et al., 2004; Mangeat et al.,
2003; Mariani et al., 2003; Suspene et al., 2004; Wiegand
et al., 2004; Yu et al., 2004b), and a failure to exclude
APOBEC3G from virions (Kao et al., 2003; Luo et al.,
2004; Mariani et al., 2003; Schafer et al., 2004; Zennou etal., 2004). The myriad of functions ascribed to Vif are
often contradictory and some may be artifacts of in vitro
studies. Decreases in reverse transcribed viral cDNA may
be one of the most controversial effects associated with vif
disruption. While most reports agree that the initiation of
reverse transcription is unaffected in the absence of Vif for
both SIV and HIV (Borman et al., 1995; Gaddis et al.,
2003; Goncalves et al., 1996; Sova and Volsky, 1993; von
Schwedler et al., 1993), effects of Vif deletion on late
products of reverse transcription are less clear. Vif
disruption in non-permissive cells has been shown to
cause little or no defect in cDNA synthesis in some studies
(Gaddis et al., 2003; Zou and Luciw, 1996) or greater than
25% reduction in cDNA synthesis during the initial round
of infection in others (Borman et al., 1995; Sova and
Volsky, 1993; von Schwedler et al., 1993). Using the most
sensitive method developed to date, quantitative real-time
PCR, we demonstrate a 90% reduction in late products of
reverse transcription (Fig. 5B), with little to no affect on
the initiation of reverse transcription (Fig. 5A). One
possible explanation for the defects in reverse transcription
observed for SIVDvif-SA are alterations in RNA secondary
structure resulting from the engineered mutations. How-
ever, this seems unlikely as replication in both Vif
permissive and non-permissive cells should have been
affected equally. It is clear from Fig. 2 that replication was
impaired only in Vif non-permissive cells. A more likely
explanation is that APOBEC3G-induced mutations target
the proviral cDNA, either directly or indirectly, for
degradation. Thus, our real-time PCR data support
degradation of SIV cDNA by uracil DNA glycosylase as
a mechanism for the antiviral activities of APOBEC3G
(Harris et al., 2003; Mariani et al., 2003).
Similar to viral replication of vif-deleted HIV (Kobaya-
shi et al., 2004; Mangeat et al., 2003; Mariani et al., 2003;
Suspene et al., 2004; Yu et al., 2004b; Zhang et al., 2003),
SIVagm (Mangeat et al., 2003; Mariani et al., 2003;
Schrofelbauer et al., 2004), and SIVmac (Mangeat et al.,
2003; Mariani et al., 2003), we observed hypermutability of
the nascent -sssDNA, specifically G to A transitions.
Reports of the mutation rate for vif-deficient HIV during
APOBEC3G overexpression are highly varied, ranging from
1.1% to 14% (Mangeat et al., 2003; Mariani et al., 2003).
Even endogenous levels of APOBEC3G induce up to 2.5%
G to A mutations in HIV lacking Vif (Zhang et al., 2003). In
concordance with previously reported studies, we observed
a significantly higher mutational frequency for SIVDvif-SA
relative to SIVmac239 in CEMx174 and H9 cells, but not in
CEM-SS cells. The percentage of G to A mutations
observed, ¨1.5%, is at the low end of those reported for
HIV. Replication of some SIV strains appears to be less
sensitive to inhibition by APOBEC3G from human cell
lines (Gaddis et al., 2003), which may explain the lower
mutational frequency we observed. Alternatively, low level
of Vif expression from the cryptically spliced mRNA (Fig.
3) may partially abrogate APOBEC3G-mediated G to A
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are available to determine if Vif was expressed at low levels.
Consistent with the hypothesis that low levels of Vif
expression occurred from the cryptically spliced product
was the nature of the G to A mutations. Some clones had
many G to A mutations while others had one or none (data
not shown). Nevertheless, as shown in Fig. 2, the growth
defects of SIVDvif-SA were severe in Vif non-permissive
cells, indicating that even low levels of Vif expression were
insufficient to support SIV replication. Our laboratory has
found that identical mutation of the HIV SA1 site results in
more severely impaired HIV replication with a higher rate of
G to A mutations than that observed for SIV. Moreover, no
evidence for alternatively spliced HIV vif mRNA or for Vif
protein synthesis was observed (B. Herrera and W.E.
Robinson, Jr., unpublished results). Thus, low level of
expression of SIV Vif from the cryptically spliced product
seems a viable interpretation of our findings that G to A
mutations are lower in SIVDvif-SA than observed for Vif
deleted HIV.
Another important finding in these studies concerns the
species specificity of Vif. SIVagm Vif fails to down regulate
human APOBEC3G (Mariani et al., 2003; Takeuchi et al.,
2005; Yu et al., 2004a). Indeed, the block of SIVagm in
some human cell lines has been attributed to this failure.
Clearly, SIVmac239 replicates in Vif non-permissive H9 and
CEMx174 cells, indicating SIVmac239 Vif interacts with
human APOBEC3G. Moreover, the G to A mutational
frequency of SIVmac239 was quite low in H9 and CEMx174
cells when Vif was expressed (Fig. 6). Thus, while some
SIV Vif proteins may differ sufficiently in sequence and
cannot interact with human APOBEC3G, not all do.
Indeed, work from several laboratories clearly indicates
HIV Vif, SIVmac239 Vif, and SIVAGM Vif show differential
abilities to interact with human, AGM, and rhesus
APOBEC3G (Bogerd et al., 2004; Mariani et al., 2003;
Yu et al., 2004a).
These studies on SIVDvif-SA identify another interesting
phenotype that may be Vif dependent. Previous reports on
HIV replication have identified that the second most
common mutation observed in the absence of Vif is A to
G (Kobayashi et al., 2004; Mangeat et al., 2003; Wiegand et
al., 2004). As indicated in Fig. 6B, A to G mutations wereName Sequence (5Vto 3V)
S-AA55 CAAAGCAGAAAGGGTCCTA
S-M667 TCCAGCACTAGCAGGTAGA
S-M661 CACTCTCCTTCAAGTCCCTG
S-MH536 CTCAATAATAAGAAGACCC
S-MH535 GTATATGTCTAAGATTCTAT
SIVDvif-SA5V GTCTATTATCGCGAAGGCAG
SIVDvif-SA3V GATCTCTGCCTTCGCGATAA
S-Vif-REV GGCTATGCCACCTCTCTAGC
S-SA1V-Rev GTAGTGATCATGTTAATTAA
S-IN-Rev TTAGCCTTTCTTCTGGGTAC
Underlined nucleotides represent introduced mutations.
* Nucleotide positions based upon SIVmac239 (accession no. M33262).common in our study as well. It is possible that A to G
conversions result from base pair misincorporation biases
inherent in RT or PCR. However, biochemical assays of SIV
RT indicate T:G mismatches are the most prevalent RT
substitutions. A:C mismatches during the first round of
synthesis would result in A to G mutations we observed;
however, these mutations were much less frequent than T:G
mismatches (Manns et al., 1991). Alternatively, A to G
mutations may represent a second class of Vif-responsive
innate antiviral editing enzymes, distinct from APOBEC3.
The RNA editing enzyme ADAR1, for example, is
expressed within T-lymphocytes and has been shown to
induce A to G mutations in hepatitis delta virus (Jayan and
Casey, 2002; Wong and Lazinski, 2002). Increased A to G
mutational frequency during SIVDvif-SA infection in H9 and
CEM-SS cells suggests that A to G mutational frequency is
suppressed by Vif, consistent with this hypothesis. How-
ever, relatively high rates of A to G mutations were also
seen during SIVmac239 replication in H9 and CEMx174 cells
with equivalent mutational frequencies between SIVmac239
and SIVDvif-SA during replication in CEMx174. Never-
theless, further studies on the possibility that Vif affects
other RNA editing enzymes should be explored.
Despite more than 20 years of research on HIV and SIV,
the role of differential RNA splicing in pathogenesis of
lentiviruses remains largely unknown. In HIV, there
appears to be a great deal of plasticity in the splicing of
mRNAs around SA2, SA3, and SA4 (Caputi and Zahler,
2002; Domsic et al., 2003; Schwartz et al., 1991). It is not
clear whether such plasticity exists for SIV. Nevertheless,
these data suggest that splicing of SIV vif is tightly
controlled at SA1. Although a cryptic splice site was
uncovered, Vif expression from this mRNA was inadequate
to counteract the anti-SIV properties present in CEMx174
and H9 cells.Materials and methods
Oligonucleotides
All oligonucleotides were synthesized and desalted by
Sigma-Genosys.Location*
ACAGAC 1022–1046 (anti-sense)
GCC 821–842 (sense)
TTC 1086–1108 (anti-sense)
TGGTCTG 10462–10488 (sense)
GTCTTC 281–306 (sense)
AGATC 5457–5482 (sense)
TAGAC 5457–5482 (anti-sense)
5649–5668 (anti-sense)
TCTTTCTG 5376–5403 (anti-sense)
TACCTTA 5556–5582 (anti-sense)
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A subclone of SIVmac239 containing a BamHI (nt 2105)
and SphI (nt 6706) fragment was constructed and used for
site-directed mutagenesis. PCR-based mutagenesis was
performed using the QuikChange kit (Stratagene). Comple-
mentary primer pairs, SIVDvif-SA5Vand SIVDvif-SA3V(1 AM),
were used in a PCR containing 250 AM dNTPs, 1
reaction buffer, and 2.5 U of Pfu Turbo polymerase. PCR
conditions were as follows: initial denaturation at 95 -C for
30 s followed by 18 rounds of cycling at 95 -C for 30 s,
55 -C for 60 s, then 68 -C for 12 min. Following DpnI
treatment to digest the parental clone, Escherichia coli
(DH5-a) cells were transformed with 2 Al of the PCR
product. Plasmids were isolated from independent colonies.
Sequencing of plasmids confirmed the introduction of only
the designed mutations. Full-length SIVDvif-SA was con-
structed in SIVmac239 using the BamHI and SphI
restriction sites.
Cells and viruses
Cells were cultured at 37 -C in RPMI-1640 containing
2 mM l-glutamine supplemented with 11.5% fetal bovine
serum (Omega Scientific Inc.). All cell lines were reduced by
half and resuspended in fresh media every other day. Human
CD4+ T-lymphoblastoid cells CEM-SS and H9, and a human
B/T lymphocyte hybrid cell line, CEMx174, were obtained
from the NIH AIDS Research and Reference Reagent
Program. Plasmids encoding SIVmac239 or SIVDvif-SA were
transformed into CEM-SS cells via single pulse electro-
poration at 200 mV for 50 ms. Infection was monitored by a
modification of IFA previously described for HIV (Robinson
et al., 1989). Fixed cells were incubated with either
polyclonal monkey sera from SIV-infected animals or
cross-reactive polyclonal human anti-HIV immune globulin,
followed by fluorescein-conjugated goat anti-human IgG.
The percentage of SIVantigen-positive cells was determined
on a Nikon epifluorescent microscope. Cells were maintained
for 6–10 days post-electroporation until cultures reached
>50% SIVantigen positive by IFA, the supernatant was then
clarified of cells by low-speed centrifugation followed by
filtration through 0.45 Am cellulose acetate filters.
Replication kinetics of SIVDvif-SA and SIVmac239
Early replication kinetics of SIVmac239 and SIVDvif-SA
were measured in CEMx174, CEM-SS, and H9 cells using
real-time PCR. Equal amounts of each virus by RT assay
were inoculated onto 1  107 cells. Next, 1  106 cells
were harvested for real-time PCR at 1, 2, 4, 8, 12, 24, 36,
48, and 72 h post-inoculation. To measure the time
necessary for each virus to spread through the culture,
IFA was performed and the percentage of cells positive for
SIV antigens was calculated over a 2- to 6-week period in
each cell line.Cell lysis and sample preparation for real-time PCR
Cell lysis was performed as previously described (Victo-
ria et al., 2003). Briefly, 1.0  106 cells were lysed in 100 Al
of lysis solution (Kellogg and Kwok, 1990) containing 100
mM KCl, 10 mM Tris–HCl (pH 8.3), 2.5 mM MgCl2, 0.5%
Tween-20, 0.5% Nonidet NP40, and 20 Ag of proteinase K.
Cells were lysed for 1 h at 60 -C, followed by heat
inactivation of proteinase K for 15 min at 95 -C.
Quantitative real-time PCR
Real-time PCR was performed using the Smart Cycler
(Cepheid) and identical conditions to those previously
reported for HIV-specific primers AA55, M661, and M667
(Victoria et al., 2003). Lysate from the equivalent of 2.0 
104 cells was used in PCR under conditions: 95 -C for 150 s
followed by 40 cycles of 95 -C for 15 s and 61 -C for 30 s.
Melt curve analysis was utilized to distinguish bona fide
products of amplification from primer dimers (Victoria et al.,
2003). PCR reactions contained 0.2 mM Tris–HCl (pH 8.4),
2.0 mMMgCl2, 50 mM KCl, 0.625 U Taq DNA polymerase
(Invitrogen), 0.2 AM of each primer, 200 AM dNTPs, and
0.25 SYBR Green I (Sigma-Aldrich or Molecular Probes)
in a 25-Al reaction volume. Primer pairs were used to detect:
-sssDNA, S-AA55/S-M667; completely synthesized SIV
cDNA, S-M661/S-M667; or two LTR circle DNA, S-
MH535/S-MH536. PCR amplification of S-MH535/S-
MH536 was carried out in an identical manner as above
except 5 Ag of non-acetylated bovine serum albumin, 0.15 M
trehalose, and 0.2% Tween-20 were added to the reaction
tubes. The extension time temperature was 59 -C and the
number of cycles was increased to 45.
Identifying the vif splice acceptor site
Total cellular RNAs were isolated according to manufac-
turer’s instructions (Gentra) from 1.0  107 CEM-SS cells
infected with either SIVmac239 or SIVDvif-SA. Next, cDNAwas
generated first by preincubation of 1 Ag of cellular RNAwith
S-Vif-REV primer for 5 min at 70 -C. Then, 200 U of
Superscript II RT (Invitrogen), 1 manufacturer’s buffer
(Invitrogen), 500 AM RNase-free dNTPs, and 10 AM DTT
were added and the reactions were heated at 42 -C for 50 min
followed by 72 -C for 15 min. PCR amplification of the
cDNA was performed using Triple Master enzyme mix
(Eppendorf). Amplification of 7 Al of cDNA from either
SIVmac239 or SIVDvif-SA was performed using 1 manufac-
turer’s buffer, 0.4 AM of S-M667, and 0.4 AM of either S-IN-
Rev or S-SA1V-Rev primers, 2.5 units of enzyme, and 200 AM
dNTPs in a 25-Al total reaction volume. Products from PCR
were separated by electrophoresis through a 1.5% agarose gel
and DNA was transferred to zeta probe membrane (BioRad
Laboratories) in 0.4 M NaOH.
S-AA55 probe was end-labeled using T4 polynucleotide
kinase (New England Biolabs) and g-[32]P-ATP. Probe was
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2.5% non-fat milk containing 100 Ag/ml sonicated salmon
sperm DNA. Unbound probe was removed by sequential 15
min washes in 2 SSC 0.5% SDS, 0.1 SSC 0.5% SDS,
and 0.1 SSC 0.1% SDS at 60 -C. Images were scanned
using a Molecular Dynamics Storm phosphorimager and
quantified using IQ tool software (Molecular Dynamics).
PCR amplified products were cloned into pGEM T-easy
vector (Promega) and sequenced.
Sequence analysis of SIVDvif-SA and SIVmac239
SIV-infected cells were lysed 48 h post-inoculation as
above. Total cell lysate was used in high fidelity PCR to
amplify the IN gene (between nucleotides 4776 and 5668)
from the proviral DNA. PCR products were cloned into the
pGEM cloning vector (Stratagene) and used for automated
sequencing (Laguna Scientific) using the T7 primer.Acknowledgments
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